U.S. Markets close in 1 hr 9 mins
  • S&P 500

    4,315.67
    -117.32 (-2.65%)
     
  • Dow 30

    33,689.61
    -895.27 (-2.59%)
     
  • Nasdaq

    14,565.70
    -478.27 (-3.18%)
     
  • Russell 2000

    2,158.33
    -78.54 (-3.51%)
     
  • Crude Oil

    70.42
    -1.55 (-2.15%)
     
  • Gold

    1,763.40
    +12.00 (+0.69%)
     
  • Silver

    22.16
    -0.14 (-0.63%)
     
  • EUR/USD

    1.1730
    -0.0001 (-0.0117%)
     
  • 10-Yr Bond

    1.3060
    -0.0640 (-4.67%)
     
  • Vix

    28.19
    +7.38 (+35.46%)
     
  • GBP/USD

    1.3655
    -0.0082 (-0.5967%)
     
  • USD/JPY

    109.3450
    -0.5500 (-0.5005%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,085.70
    -48.68 (-4.29%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of the thinly-traded, nano-cap penny stock Daré Bioscience Inc (NASDAQ: DARE) were trading higher Monday.

What Happened

Daré, which focuses on women's health, said Monday that its BV1 — a thermosetting hydrogel containing clindamycin phosphate 2% — has been given the Qualified Infectious Disease Product, or QIDP, designation by the FDA for the treatment of bacterial vaginosis in women.

BVI is a viscous liquid which goes through solution-to-gel transition using the body temperature as a trigger, which facilitates easy direction of the product to the site of infection.

"Receiving QIDP designation for DARE-BV1 for the treatment of BV is validation that BV is a serious infection for which current treatment options are inadequate," Daré CEO Sabrina Martucci Johnson said in a statement.

Why It's Important

The clinical cure rates for currently approved products in bacterial vaginosis are about 37-39%, and the condition affects over 21 million among women ages 14-49, according to Daré.

The proof-of-concept study of BV1 showed an 86% clinical cure rate in the evaluable subjects at the test-of-cure visit after a single administration.

The QIDP designation is meant to incentivize development of antibacterial and antifungal drug products that treat serious or life-threatening infections.

The designation confers:

  • a five-year exclusivity extension, added to any exclusivity for which a QIDP qualifies upon FDA approval

  • The QIDP designation also makes the product candidate eligible for Fast Track designation and Priority Review

What's Next

Daré said it plans to start a late-stage study of BVI in about 250 women in the fourth quarter of 2019.

The company said it believes the Phase 3 study, if successful, would be sufficient for approval of BV1 to treat bacterial vaginosis.

Daré shares were rising 2.67% to 77 cents at the time of publication Monday.

Related Links:

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.